In Alzheimer’s disease, SET in the brain is translocated from the neuronal nucleus to the cytoplasm, where it inhibits PP2A activity and promotes abnormal phosphorylation of Tau (Arif et al. 2014). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.